Caladrius Biosciences, Inc. CLBS Income Statement

Caladrius biosciences, inc. (CLBS)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Operating Expenses:
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,804	22,487	20,204	18,433	17,055	17,938	16,740	16,329	16,200	14,668	13,341	14,068	13,081	14,329	-2,349	-4,606	-5,768	10,050	40,454	57,684	0	0	0
Cost of revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,018	20,158	18,139	17,343	15,221	15,678	14,859	13,822	14,380	12,947	12,112	12,884	11,385	11,949	127	-1,728	-2,674	8,646	29,191	40,211	0	0	0
Gross profit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,477	-2,878	-3,094	1,403	11,262	17,473	0	0	0
Research and development
10,258	10,797	9,538	8,235	7,370	7,594	10,738	12,224	14,378	15,843	14,566	14,338	14,549	16,699	16,502	19,859	22,971	23,899	30,889	33,043	31,238	29,194	24,322	20,339	18,515	16,917	14,580	12,922	11,665	10,451	9,323	8,035	6,912	7,720	7,566	8,159	0	0	0
Impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
9,299	9,295	9,268	9,262	9,050	9,393	9,773	10,654	11,940	11,750	9,740	9,566	9,050	12,802	17,178	19,556	25,375	30,005	31,467	34,215	32,924	30,806	30,241	27,904	24,780	21,612	20,904	21,294	21,704	22,315	20,300	20,328	24,464	27,687	33,785	35,675	0	0	0
Total operating expenses
19,557	20,092	18,806	17,497	16,420	16,987	20,511	22,878	26,319	27,593	18,078	17,676	17,371	29,501	98,965	109,509	133,639	136,336	89,896	94,001	79,385	75,679	69,423	62,066	57,676	51,477	57,037	52,793	47,711	44,715	29,624	28,364	31,377	35,407	41,352	0	0	0	-
Operating loss
-19,557	-20,092	-18,806	-17,497	-16,420	-16,987	-20,511	-22,878	-26,319	-27,593	-25,568	-25,165	-24,861	-29,501	-83,915	-88,571	-106,834	-113,849	-69,692	-75,568	-62,329	-57,740	-52,682	-45,736	-41,476	-36,808	-34,257	-33,033	-31,674	-30,385	-32,101	-31,242	-34,471	-34,004	-30,089	-26,362	0	0	0
Other income:
Investment income, net
584	740	849	888	873	824	721	684	495	273	141	-30	-26	23	13,344	12,929	18,275	17,723	8,387	8,110	2,569	2,926	-2,925	-2,058	-1,815	-1,614	-4,102	-4,357	-4,391	-4,314	524	1,892	2,423	2,085	1,644	500	0	0	0
Interest expense
-	-	0	0	-	5	10	19	222	378	520	880	1,011	1,779	2,108	2,292	2,504	2,128	2,023	1,653	1,212	755	456	372	332	281	425	711	1,096	1,576	1,815	2,064	2,319	2,647	2,201	1,575	0	0	0
Total other income
584	740	849	888	871	819	710	664	273	-105	-379	-910	-1,037	-1,755	11,236	10,636	15,770	15,595	6,363	6,456	1,357	2,170	-3,382	-2,430	-2,147	-1,896	-4,528	-5,068	-5,487	-5,891	-1,291	-172	104	-561	-557	-1,074	0	0	0
Loss before benefit from income taxes and noncontrolling interests
-	-	-	-	-	-	-	-	-	-27,698	-25,947	-26,076	-25,899	-31,257	-72,679	-77,935	-91,063	-98,254	-63,328	-69,111	-60,972	-55,570	-56,065	-48,167	-43,623	-38,705	-38,785	-38,102	-37,162	-36,276	0	0	0	-	-	-	-	-	-
Loss from continuing operations before provision for income taxes and noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Income Tax Expense (Benefit)
-	-	-	-	-	-	-	-	-	-11,527	-8,354	-5,940	-53	0	-13,580	-13,533	-17,236	-17,243	-3,856	-3,855	-104	-104	429	427	827	780	316	272	-175	-175	0	0	0	-	-	0	0	0	0
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-16,171	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-36,101	-30,335	-31,873	0	-	0	0	-	-	-
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
-	-	-	-	-	-	-	-	-	38,399	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-47,138	-48,048	-22,315	-22,016	0	0	0	-	-
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-18,973	-19,352	-17,957	-16,609	-15,549	-16,168	-15,505	-15,504	27,037	22,228	19,034	15,294	-31,055	-33,309	-60,448	-64,553	-73,826	-81,010	-59,472	-65,256	-60,867	-55,466	-56,494	-48,594	-44,451	-39,485	-42,110	-41,229	-66,026	-66,369	-80,042	-78,974	-56,089	-56,582	-33,560	-29,994	0	0	0
Less - net income attributable to noncontrolling interests
11	9	7	7	3	-1	54	-65	-119	-182	-290	-230	-239	-241	-221	-179	-146	-124	-171	-357	-489	-593	-699	-702	-588	-504	-358	-212	-249	-287	-283	-238	0	-	0	0	-	-	-
Less - net income attributable to noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-53,769	-57,273	-56,209	-46,309	-47,134	-35,265	-33,292	0	0	0
Less - net loss from discontinued operations attributable to noncontrolling interests
-	-	-	-	-	-	-	-	-	-569	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,312	-12,459	-12,451	0	-	0	0	-	-	-
Warrant inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Warrant inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Payment for warrant inducement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Preferred dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	414	517	0	-	0	0	-	-	-
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders
-	-	0	0	-	-	0	0	0	-	0	0	0	-	-59,895	-64,388	-73,679	-80,885	-59,300	-64,899	-60,377	-54,872	-55,795	-47,892	-43,862	-38,981	-42,216	-42,636	-54,654	-55,310	-58,681	-56,687	-46,870	-47,774	-35,773	-33,703	0	0	0
Basic and diluted loss per share
Preferred dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	395	478	560	639	561	0	0	-	0
Loss from continuing operations
-	-	-	-	-	-	-	-	-	-15,989	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-35,814	-32,405	-30,452	-33,372	-34,266	0	0	0	-	-
Income from discontinued operations - net of taxes
-	-	-	-	-	-	-	-	-	38,968	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,955	-15,558	-16,170	0	-	0	0	-	-	-
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders
-	-	0	0	-	-	0	0	0	-	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-42,216	-42,636	-54,654	-55,310	-58,681	-56,687	-46,870	-47,774	-35,773	-33,703	0	0	0
Basic and diluted loss per share:
Continuing operations (in usd per share)
-	-	-	-	-	-	-	-	-	-	-0.38	-0.22	-0.78	-	-0.95	-1.30	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.42	-0.57	-0.53	-0.07	-0.07	-0.07	-0.13	-0.12	-	-
Discontinued operations (in usd per share)
-	-	-	-	-	-	-	-	-	-	0.00	4.56	-0.33	-	-0.13	-0.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.31	0.01	-0.99	-0.01	-0.12	-0.01	-0.01	-0.01	-	-
Caladrius Biosciences, Inc. common stockholders (in usd per share)
-0.38	-0.48	-0.47	-0.49	-0.44	-0.37	-0.36	-0.42	-0.52	-	-0.38	4.34	-1.12	-	-1.09	-1.33	-2.09	-10.26	-2.06	-3.84	-0.51	-0.31	-0.48	-0.40	-0.49	-0.46	-0.45	-0.46	-0.53	-1.75	-0.64	-1.53	-0.08	-0.19	-0.08	-0.13	-0.14	-0.13	-0.11
Weighted average common shares outstanding
Weighted average common shares outstanding (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,698	-84,699	14,819	13,441	111,806	106,071	94,102	80,567	73,654	56,777	48,771
Basic and diluted shares
10,623	10,469	10,411	10,393	10,027	9,862	9,745	9,592	9,557	-	9,093	8,926	8,386	-	6,323	5,907	5,738	-	5,523	4,457	37,594	-	35,053	31,739	28,120	-	20,203	18,503	-	-	-	-	-	-	-	-	-	-	-
Available for sale securities - net unrealized (loss) gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss attributable to noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average common shares outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94,089	80,581	73,654	56,777	48,771